Open Trials
Ovary
AGO-OVAR 26 / MATAO
MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS (Low Grade Ovarian cancer Sub-study)
AGO-OVAR 27 / WoO
Window-of-opportunity proof-of-concept, non-randomized, open-label, phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (EOC)
AGO-OVAR 28
Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
AGO-OVAR 2.34 / MIROVA
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy
AGO-OVAR 2.41 / TEDOVA
Randomized Phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI®) with or without anti-PD1 (Pembrolizumab) versus best supportive care as maintenance treatment in platinum-sensitive recurrent ovarian cancer patient with controlled disease after Platinum-based chemotherapy
Endometrium / Vulva / Cervix
Surgical and translational issues
AGO-OVAR OP.6 ECLAT
Pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer at high risk of recurrence. A multicenter, prospective randomized controlled trial.
AGO-OVAR OP.9 SENTICOL III
International validation study of sentinel node biopsy in early cervical cancer
AGO-TR 2
Prevalence of somatic and germline mutations in patients with primary or relapsed endometrial carcinomas
AGO-TR 3 / AC2202
Observational analysis of the association of drug activity measured in viable tumour tissues ex vivo and clinical response in ovarian cancer: a basic research study